Genomatica helps DuPont Tate & Lyle achieve BDO milestone
DuPont Tate & Lyle Bio Products has commercially manufactured more than five million pounds (2,000t) of 1,4-Butanediol (BDO) at its US biochemical plant, employing Genomatica's bio-based production process during a five-week campaign in late 2012.
The technology, which first demonstrated the ability for a microorganism to produce BDO in 2008, manufactures the chemical through direct fermentation and uses conventional sugars as feedstock.
Genomatica chief executive officer Christophe Schilling said this was a sizable commercial-scale production campaign.
"Partnering with DuPont Tate & Lyle brought us biochemical process know-how at significant scale to make the leap from demonstration to commercial volumes," Schilling added.
"The success of this campaign is a significant milestone for our technology and for the biochemical industry."
The partnership has utilised DuPont Tate & Lyle's commercial-scale batch fermentation operation to feed the plant's continuous downstream processing, according to Genomatica.
DuPont Tate & Lyle Bio Products president Todd Sutton said utilising Genomatica's developments, the company demonstrated the flexibility of its bioprocessing capability.
"We congratulate the Genomatica team on the development of their BDO technology and look forward to continued collaboration," Sutton added.
The intermediate chemical BDO is used in a wide range of applications, including athletic apparel, electronics and automotive applications.
DuPont Tate & Lyle, a joint venture between DuPont and Tate & Lyle, has been operating its biochemical plant in Tennessee since 2006, manufacturing 1,3-propanediol (PDO) at commercial volumes.
Image: More than 2,000t of BDO were produced using Genomatica's BDO technology in a five week campaign. Photo courtesy of Genomatica.